In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y2 receptor
Rationale The lack of potent, selective, brain penetrant Y 2 receptor antagonists has hampered in vivo functional studies of this receptor. Objective Here, we report the in vitro and in vivo characterization of JNJ-31020028 ( N -(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophe...
Gespeichert in:
Veröffentlicht in: | Psychopharmacology 2010-02, Vol.208 (2), p.265-277 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Rationale
The lack of potent, selective, brain penetrant Y
2
receptor antagonists has hampered in vivo functional studies of this receptor.
Objective
Here, we report the in vitro and in vivo characterization of JNJ-31020028 (
N
-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a novel Y
2
receptor antagonist.
Methods
The affinity of JNJ-31020028 was determined by inhibition of the PYY binding to human Y
2
receptors in KAN-Ts cells and rat Y
2
receptors in rat hippocampus. The functional activity was determined by inhibition of PYY-stimulated calcium responses in KAN-Ts cells expressing a chimeric G protein Gqi5 and in the rat vas deferens (a prototypical Y
2
bioassay). Ex vivo receptor occupancy was revealed by receptor autoradiography. JNJ-31020028 was tested in vivo with microdialysis, in anxiety models, and on corticosterone release.
Results
JNJ-31020028 bound with high affinity (pIC
50
= 8.07 ± 0.05, human, and pIC
50
= 8.22 ± 0.06, rat) and was >100-fold selective versus human Y
1
, Y
4
, and Y
5
receptors. JNJ-31020028 was demonstrated to be an antagonist (pK
B
= 8.04 ± 0.13) in functional assays. JNJ-31020028 occupied Y
2
receptor binding sites (~90% at 10 mg/kg) after subcutaneous administration in rats. JNJ-31020028 increased norepinephrine release in the hypothalamus, consistent with the colocalization of norepinephrine and neuropeptide Y. In a variety of anxiety models, JNJ-31020028 was found to be ineffective, although it did block stress-induced elevations in plasma corticosterone, without altering basal levels, and normalized food intake in stressed animals without affecting basal food intake.
Conclusion
These results suggest that Y
2
receptors may not be critical for acute behaviors in rodents but may serve modulatory roles that can only be elucidated under specific situational conditions. |
---|---|
ISSN: | 0033-3158 1432-2072 |
DOI: | 10.1007/s00213-009-1726-x |